# Debate Matchup Judgment Report

**GLM-5.2 (max)** vs **Grok 4.6 (high)**

- Paired result: **Tie**
- Mean entertainment: `7.83 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Public health systems should treat genomic newborn screening as opt-out rather than opt-in, limited to conditions with effective early interventions.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0540__glm-5-2__grok-4.6-high__s0__tpl_placement_active_20260813a.md): PRO = **GLM-5.2 (max)**, CON = **Grok 4.6 (high)**
- [Debate B transcript](../../../transcripts/prop_0540__grok-4.6-high__glm-5-2__s1__tpl_placement_active_20260813a.md): PRO = **Grok 4.6 (high)**, CON = **GLM-5.2 (max)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0540__glm-5-2__grok-4.6-high__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **GLM-5.2 (max)**, CON = **Grok 4.6 (high)**
- Judged result: Unanimous `3-0` for **GLM-5.2 (max)**.
- Entertainment scores: `8`, `7`, `8`
- Mean signed raw margin (PRO+): `+1.67`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = GLM-5.2 (max) (PRO); B = Grok 4.6 (high) (CON) | GLM-5.2 (max) | +1.5 | +1.27 | 8.0 |
| Muse Spark 1.1 (high) | A = Grok 4.6 (high) (CON); B = GLM-5.2 (max) (PRO) | GLM-5.2 (max) | +1.5 | +1.59 | 7.0 |
| Qwen 3.7 Max | A = GLM-5.2 (max) (PRO); B = Grok 4.6 (high) (CON) | GLM-5.2 (max) | +2.0 | +1.70 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = GLM-5.2 (max) (PRO); B = Grok 4.6 (high) (CON)): Side A won by successfully narrowing the debate to targeted, bounded panels, which neutralized Side B's strongest arguments about permanent genomic files and secondary findings. Side A then effectively weighed the remaining harm (in-loci uncertainty) against the accepted noise of traditional screening, leaving Side A's core impact of preventing irreversible harm functionally unmitigated.
  Most decisive rebuttal noted: Side A's second rebuttal and closing sequence effectively equated the 'noise' of targeted genomic testing (in-loci variants and carrier status) with the already-accepted noise of traditional heel-prick testing (false positives and family follow-ups).
- **Muse Spark 1.1 (high)** (A = Grok 4.6 (high) (CON); B = GLM-5.2 (max) (PRO)): PRO won the scope fight. The motion limits screening to conditions with effective early interventions, and PRO showed a bounded gene-panel plus sample destruction is a laboratory fact, not whole-genome banking, which CON partially conceded. That undercut CON's permanent-file and inevitable-expansion claim, while PRO's SMA uneven-coverage rebuttal undercut redundancy. CON's remaining ledger-vs-chemistry distinction and medicalization concerns are plausible but PRO's welfare asymmetry — opt-in silently excludes asymptomatic children via missed forms, hitting disadvantaged hardest, while opt-out defaults to treatment with genuine exit — was never answered.
  Most decisive rebuttal noted: B's R2 A2: bounded analysis is a laboratory fact with sample destruction, exposing CON's conflation of targeted actionable screening with whole-genome banking and collapsing the reusable-file/panel-expansion route.
- **Qwen 3.7 Max** (A = GLM-5.2 (max) (PRO); B = Grok 4.6 (high) (CON)): Side A successfully leveraged the motion's constraint ("limited to conditions with effective early interventions") to neutralize Side B's slippery slope and whole-genome concerns. A's introduction of SMA as a condition requiring molecular testing effectively answered B's challenge about the necessity of genomic screening over biochemical assays. Furthermore, A consistently won the clash on the consent mechanism, demonstrating that "making opt-in easy" does not eliminate the structural friction that disproportionately harms marginalized groups, leaving B's primary alternative inadequate.
  Most decisive rebuttal noted: Side A's Rebuttal 2, where they introduced spinal muscular atrophy (SMA) to prove that biochemical panels are insufficient for all actionable conditions, and clarified that bounded genetic analysis physically prevents the sequencing of non-target loci, dismantling Side B's "reusable whole-genome file" argument.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0540__grok-4.6-high__glm-5-2__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **Grok 4.6 (high)**, CON = **GLM-5.2 (max)**
- Judged result: Unanimous `3-0` for **Grok 4.6 (high)**.
- Entertainment scores: `9`, `7`, `8`
- Mean signed raw margin (PRO+): `+1.87`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = Grok 4.6 (high) (PRO); B = GLM-5.2 (max) (CON) | Grok 4.6 (high) | +1.8 | +1.53 | 9.0 |
| Muse Spark 1.1 (high) | A = GLM-5.2 (max) (CON); B = Grok 4.6 (high) (PRO) | Grok 4.6 (high) | +1.8 | +1.91 | 7.0 |
| Qwen 3.7 Max | A = Grok 4.6 (high) (PRO); B = GLM-5.2 (max) (CON) | Grok 4.6 (high) | +2.0 | +1.70 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = Grok 4.6 (high) (PRO); B = GLM-5.2 (max) (CON)): Side A won by decisively outweighing the harms of data retention with the irreversible physical harm of missed early diagnoses. Side A successfully cornered Side B on the claim that missed diagnoses under opt-in are "fixable," sharply pointing out that this only fixes the system's paperwork, not the child's closed treatment window.
  Most decisive rebuttal noted: Side A's response in Closing (A5.1) to Side B's claim that a missed diagnosis is a "visible failure" that is "fixable": A pointed out that calling a missed diagnosis fixable "describes a system's paperwork, not a child's body."
- **Muse Spark 1.1 (high)** (A = GLM-5.2 (max) (CON); B = Grok 4.6 (high) (PRO)): PRO (B) kept the proposition tightly scoped to actionable, time-sensitive conditions and answered CON's central distinction. CON's live route was that a genome is a permanent re-interpretable archive and that panels inevitably expand, making opt-out untrustworthy. B neutralized it with a technical fix – assay only actionable loci so no genome file exists to reanalyze and destroy residual spots – shifting the risk from inherent to governance. B's error-asymmetry weighing – a blank form under opt-in costs an irrecoverable treatment window, while an unrefused screen under opt-out can be refused and data rules tightened – was never matched. CON's replies conceded a signature does not freeze committees and evaded B's Q1 about which error to absorb, leaving PRO with the cleaner path to victory.
  Most decisive rebuttal noted: B4.1-A2: B's answer that a targeted panel never creates a whole-genome file plus that panel expansion is a governance problem either way directly undercut A1.1/A2.8 archive and enforcement arguments and turned the debate to irreversible harm vs rewritable policy.
- **Qwen 3.7 Max** (A = Grok 4.6 (high) (PRO); B = GLM-5.2 (max) (CON)): Side A won by decisively framing the core tradeoff as the child's irreversible physical harm versus the system's administrative convenience and data governance risks. Side A's rebuttal to Side B's claim that missed diagnoses under opt-in are "visible and fixable" was devastating, pointing out that fixing paperwork does not restore a child's lost treatment window. Side A also effectively neutralized the data privacy concerns by distinguishing between targeted assays and whole-genome sequencing, keeping the debate tightly focused on the proposition's limits.
  Most decisive rebuttal noted: Side A's closing rebuttal to Side B's "visible and fixable" argument, sharply noting that calling a missed diagnosis "fixable" describes the system's paperwork, not the child's body, effectively neutralizing Side B's main weighing mechanism.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0540`
- Side-swap group ID: `prop_0540__glm-5-2__grok-4.6-high__tpl_placement_active_20260813a`
- Raw paired winner: **Tie**
- Mean normalized margin for GLM-5.2 (max): `-0.10`
- Complete side swap: `yes`
- Included in ratings: `yes`
